• Symphony RCT met primary endpoint of more diabetic foot ulcers healing within 12 weeks
• Results expected to support Symphony's clinical adoption and future US reimbursement
• Publication of full study results anticipated in coming months

Aroa Biosurgery Limited (ASX: ARX) has announced the completion of its randomised controlled trial (RCT) for Symphony, its Cellular, Acellular and Matrix-like Product (CAMP) designed for use in hard to heal wounds including diabetic foot ulcers and venous leg ulcers. The Symphony RCT was a prospective, multi-centre, randomised trial comparing Symphony against Standard of Care (SOC), with treatment evaluated over a 12-week period. The primary study endpoint assessed whether more diabetic foot ulcers (DFUs) healed within the 12-week period when treated with Symphony versus SOC treatment. Preliminary findings indicate that the study achieved the primary endpoint, with the Company believing these results will further support Symphony's clinical efficacy in the management of DFUs. Publication of the full study results is expected to meet the rigorous clinical evidence thresholds that the Company expects are likely to be proposed in future reimbursement policy, supporting both Symphony's clinical adoption in chronic, complex wounds and anticipated future US reimbursement requirements.